Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVX70371 therapeutic HBV vaccine in healthy adults
NCT06989788Phase 1Completed
- Sponsor
- AstriVax Therapeutics
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Viral Vector Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing AVX70371 with Placebo (2 arms). Primary endpoints: Occurrence of solicited adverse events, Occurrence of unsolicited adverse events and 3 more. Started May 2025; status: completed.
02
Drugs
AVX70371
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06989788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989788.